LHRH analogues and PCO disease: validity of the use of enantone depot in the treatment of the disease.
The Authors have been showed the utility of LHRH analogues in the treatment of PCO disease, through hormonal dosages and echographic examination made before, during and after the therapy both with Enantone depot, CPA and EE2, and with only CPA and EE2 of control cases. The association of analogue to traditional therapy has determined a more speedy reduction of haematic levels of LH, T free, DHEA-S, than the ones we have found in control case, an evident reduction (50%) of pilonidal growth and an important improvement of acne and seborrhea.
Chair of Obstetrical and Gynaecological Pathology, University of Bari, Italy.
F
F
Vitale
P
P
Ruggieri
D000293:Adolescent; D000328:Adult; D017373:Cyproterone Acetate / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006728:Hormones / Q000097:blood; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D016729:Leuprolide